Answer:C). A phospholipid bilayer with proteins
Explanation: A cell membrane is a phospholipid bilayer with proteins embedded in it. The fatty acyl chains of the phospholipids are non polar and hydrophobic while the phosphate groups are polar and hydrophilic. The hydrophobic regions of the phospholipids interact with each by facing each other, forming a bilayer with a fluid interior. The polar head groups face outward interacting with the external environment of the cell. Proteins are embedded in this bilayer and they float in this sea of phospholipids. Proteins anchored to the membrane through interactions between the hydrophobic regions of the phospholipids and the amino acid side chains of the proteins. These lipids and proteins swim laterally in each face of the bilayer but movement from one face of the bilayer to another is restricted.
Yes it does. Are you trying to find out the name of the Membrane? if So, it's called: Semipermeable
The answer is LDL (Low Density Lipoprotein)
Arteriosclerosis is the build up of cholesrol on the inner walls of the arteries. In the long run, arteriosclerosis reduces the diameter of the blood vessels, causing high blood pressure.
The endothelial cells of arteries have receptors that facilitate binding and transportation of the LDL hence facilitation of their accumulation in the blood vessels.
In 15 patients with severe congenital ADAMTS-13 deficiency (plasma ADAMTS-13 activity 6%), the safety, tolerability, and pharmacokinetics of recombinant ADAMTS-13 were examined.
What is pharmacokinetics?
Pharmacokinetics (PK) is the study of how the body responds to drugs over the full exposure period (medications for the sake of this article). Pharmacodynamics, which closely evaluates the drug's impact on the body, is closely related to this yet clearly distinct from it. Absorption, distribution, metabolism, and excretion are the four primary variables this field often evaluates (ADME). Understanding these processes gives medical professionals the freedom to recommend and deliver drugs that will have the most benefit and the lowest danger, as well as to make adjustments as needed in light of the diverse physiology and lifestyles of their patients.
No significant side effects and no anti-ADAMTS-13 antibodies were found. BAX 930 was well tolerated. Adolescents and adults that received a single dose of BAX 930 at 5, 20, or 40 U/kg body weight showed approximately dose proportional maximum plasma concentration (Cmax [U/mL]) and area under the concentration-time curve (AUC [hU/mL]). Individual ADAMTS-13:Ag and activity levels increased in a dose-related manner and peaked within an hour. A dose-dependent persistence of von Willebrand factor (VWF) cleavage products caused by ADAMTS-13 and a smaller VWF multimeric size were seen with increasing BAX 930 dosages. It was shown in this investigation that BAX 930's pharmacokinetic parameters were similar to those predicted in earlier plasma infusion trials and that pharmacodynamic activity was present.
Complete Question
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
To know more about pharmacokinetics, go to URL
brainly.com/question/13355142
#SPJ4
